{"id":"mr308","safety":{"commonSideEffects":[{"rate":null,"effect":"Taste disturbance"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"P2X3 receptors are ion channels expressed on nociceptive nerve fibers that mediate pain transmission when activated by extracellular ATP. By blocking P2X3, MR308 reduces the excitability of pain-sensing neurons and dampens pain signal propagation to the central nervous system. This mechanism is particularly relevant for chronic pain conditions where ATP-mediated signaling contributes to persistent pain states.","oneSentence":"MR308 is a selective antagonist of the P2X3 receptor that reduces pain signaling in sensory neurons.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:22:14.167Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic cough"},{"name":"Neuropathic pain"}]},"trialDetails":[{"nctId":"NCT03062644","phase":"PHASE3","title":"Efficacy and Safety in a Randomised Acute Pain Study of MR308: STARDOM2.","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2017-04-05","conditions":"Acute Pain","enrollment":1138},{"nctId":"NCT02982161","phase":"PHASE3","title":"Efficacy and Safety in a Randomised Acute Pain Study of MR308 (Tramadol/Celecoxib).","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2016-12-28","conditions":"Acute Pain","enrollment":818}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tramadol/Celecoxib","Tramadol","Celecoxib","Placebos"],"phase":"phase_3","status":"active","brandName":"MR308","genericName":"MR308","companyName":"Mundipharma Research GmbH & Co KG","companyId":"mundipharma-research-gmbh-co-kg","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MR308 is a selective antagonist of the P2X3 receptor that reduces pain signaling in sensory neurons. Used for Chronic cough, Neuropathic pain.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":12,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}